Quick Answer
PROVECTUS BIOPHARMACEUTICALS, INC. reported Total Revenue of $336.1 thousand for the year ending 2025.
- PROVECTUS BIOPHARMACEUTICALS, INC. showed a decrease of -45.5% in Total Revenue from 2024 to 2025.
- This data is from PROVECTUS BIOPHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: $187.6 thousand | Q2 2022: $321.7 thousand | Q3 2022: $314.9 thousand | Q1 2023: $205.0 thousand | Q2 2023: $161.8 thousand | Q3 2023: $69.7 thousand | Q1 2024: $238.1 thousand | Q2 2024: $255.0 thousand | Q3 2024: $109.7 thousand | Q1 2025: $278.6 thousand | Q2 2025: $57.5 thousand.
- Over the full 4 years of available data (2022 to 2025), PROVECTUS BIOPHARMACEUTICALS, INC.'s Total Revenue has declined by 66.0%.
- Historical annual values: Fiscal year 2025: $336.1 thousand | Fiscal year 2024: $617.1 thousand | Fiscal year 2023: $557.7 thousand | Fiscal year 2022: $989.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: